Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Original Publication Date
Article Source
External Web Content
Summary Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and…
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry
Ravulizumab, a second-generation complement component 5 inhibitor (C5i) derived from eculizumab eculizumab:
2026 New Brunswick Patient and Family Conference
CONFERENCE LOCATION:
Heldrich Hotel
10 Livingston Avenue
New Brunswick, NJ 08901
Parking:
Complimentary hotel valet parking
Cord Blood Transplant
Topic(s)
Bone Marrow Transplant
Presenter(s)
Filippo Milano, MD, PhD
During this webinar, Dr. Filippo Milano will discuss cord blood transplant and its role in treating blood cancers and hematological disorders. He will discuss the unique benefits of cord blood as a stem cell source, recent advances in transplantation techniques, and strategies to…
Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation.
Original Publication Date
Article Source
External Web Content
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
Original Publication Date
Article Source
External Web Content
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…
Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT: a 20-year single-center experience
Original Publication Date
Article Source
External Web Content
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or…